Skip to main content
OpenTrials

Clinical trial condition

Diabetes Mellitus, Type 2

Explore clinical trials studying Diabetes Mellitus, Type 2. Study availability and eligibility vary by location and protocol.

2,679 public trials 158 recruiting studies
Refine in advanced search Browse all conditions

Diabetes Mellitus, Type 2 trial results

Completed

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

NCT01306214

Conditions
Body Weight, Diabetes Mellitus, Diabetes Mellitus, Type 2, +10 more
Locations
  • 1245.49.10005 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 1245.49.10011 Boehringer Ingelheim Investigational Site Chandler, Arizona, United States
  • 1245.49.10004 Boehringer Ingelheim Investigational Site Tucson, Arizona, United States
  • 1245.49.10002 Boehringer Ingelheim Investigational Site Corona, California, United States
View all 103 locations
View Trial Details
Completed

Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

NCT01368081

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1245.52.023 Boehringer Ingelheim Investigational Site Adachi-ku, Tokyo, Japan
  • 1245.52.048 Boehringer Ingelheim Investigational Site Aki-gun, Hiroshima, Japan
  • 1245.52.012 Boehringer Ingelheim Investigational Site Annaka, Gunma, Japan
  • 1245.52.087 Boehringer Ingelheim Investigational Site Atami, Shizuoka, Japan
View all 87 locations
View Trial Details
Completed

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

NCT01210001

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1245.19.10056 Boehringer Ingelheim Investigational Site Muscle Shoals, Alabama, United States
  • 1245.19.10162 Boehringer Ingelheim Investigational Site Glendale, Arizona, United States
  • 1245.19.10161 Boehringer Ingelheim Investigational Site Phoenix, Arizona, United States
  • 1245.19.10046 Boehringer Ingelheim Investigational Site Tempe, Arizona, United States
View all 68 locations
View Trial Details
Completed

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

NCT01159600

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1245.23.10145 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 1245.23.10046 Boehringer Ingelheim Investigational Site Tempe, Arizona, United States
  • 1245.23.10095 Boehringer Ingelheim Investigational Site Huntington Park, California, United States
  • 1245.23.10109 Boehringer Ingelheim Investigational Site Huntington Park, California, United States
View all 148 locations
View Trial Details
Completed

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

NCT00881530

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1245.24.101001 Boehringer Ingelheim Investigational Site Mission Viejo, California, United States
  • 1245.24.101028 Boehringer Ingelheim Investigational Site Spring Valley, California, United States
  • 1245.24.101027 Boehringer Ingelheim Investigational Site Walnut Creek, California, United States
  • 1245.24.101004 Boehringer Ingelheim Investigational Site Clearwarter, Florida, United States
View all 137 locations
View Trial Details
Completed

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

NCT01164501

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +10 more
Locations
  • 1245.36.10014 Boehringer Ingelheim Investigational Site Anaheim, California, United States
  • 1245.36.10019 Boehringer Ingelheim Investigational Site Lomita, California, United States
  • 1245.36.10017 Boehringer Ingelheim Investigational Site Plantation, Florida, United States
  • 1245.36.10009 Boehringer Ingelheim Investigational Site West Palm Beach, Florida, United States
View all 127 locations
View Trial Details
Completed

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

NCT01177813

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1245.20.10124 Boehringer Ingelheim Investigational Site Mesa, Arizona, United States
  • 1245.20.10108 Boehringer Ingelheim Investigational Site Phoenix, Arizona, United States
  • 1245.20.10150 Boehringer Ingelheim Investigational Site Hot Springs, Arkansas, United States
  • 1245.20.10154 Boehringer Ingelheim Investigational Site Chino, California, United States
View all 124 locations
View Trial Details
Completed

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

NCT00749190

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1245.10.10026 Boehringer Ingelheim Investigational Site Chula Vista, California, United States
  • 1245.10.10001 Boehringer Ingelheim Investigational Site Mission Viejo, California, United States
  • 1245.10.10011 Boehringer Ingelheim Investigational Site Pasadena, California, United States
  • 1245.10.10028 Boehringer Ingelheim Investigational Site Spring Valley, California, United States
View all 116 locations
View Trial Details

Related conditions